Al-Jighefee Hadeel T, Najjar Hoda, Ahmed Muna Nizar, Qush Abeer, Awwad Sara, Kamareddine Layla
Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.
Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar.
Vaccines (Basel). 2021 Oct 18;9(10):1196. doi: 10.3390/vaccines9101196.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents against SARS-CoV-2 was a dire need. To date, various platforms have been utilized for SARS-CoV-2 vaccine development, and over 200 vaccine candidates have been produced, many of which have obtained the United States Food and Drug Administration (FDA) approval for emergency use. Despite this successful development and licensure, concerns regarding the safety and efficacy of these vaccines have arisen, given the unprecedented speed of vaccine development and the newly emerging SARS-CoV-2 strains and variants. In this review, we summarize the different platforms used for Coronavirus Disease 2019 (COVID-19) vaccine development, discuss their strengths and limitations, and highlight the major safety concerns and potential risks associated with each vaccine type.
截至2020年3月,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)已成为大流行病,引发了全球危机并夺走了数百万人的生命。为了遏制这一大流行病并减轻其对社会、经济和公共卫生的影响,迫切需要开发针对SARS-CoV-2的疫苗和抗病毒药物。迄今为止,各种平台已被用于SARS-CoV-2疫苗的开发,已生产出200多种候选疫苗,其中许多已获得美国食品药品监督管理局(FDA)的紧急使用批准。尽管取得了这一成功的开发和许可,但鉴于疫苗开发的前所未有的速度以及新出现的SARS-CoV-2毒株和变体,人们对这些疫苗的安全性和有效性产生了担忧。在这篇综述中,我们总结了用于2019冠状病毒病(COVID-19)疫苗开发的不同平台,讨论了它们的优势和局限性,并强调了与每种疫苗类型相关的主要安全问题和潜在风险。